No 02 2017

The company has announced the initiation of a first-in-human Phase 1/2a clinical trial of GLIX1 in patients with recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.

The company has announced final efficacy and safety results from its Phase II ATLAS-IT-05 study evaluating intratumoral ruxotemitide (LTX-315) in combination with pembrolizumab in patients with advanced melanoma who have progressed following prior checkpoint inhibitor therapy.

It’s one thing to “do” physics – but it’s another to explain its fundamentals to others, and the role that physics and other sciences play in their lives.

This is according to Swecare's Health Export Barometer 2026 launched today, April 21.

Encare will be awarded the Swecare Export Award 2026 and Bioservo will be named a Rising Star.

Nanologica has received an order of appx. SEK 2 million for the company’s silica-based purification media NLAB Saga.

VTT-originated startup Proteins.1 aims to bring PCR-like amplification and simplicity to omics.